AVITA Medical, Inc.
AVITA Medical, Inc. (RCEL) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for AVITA Medical, Inc. (RCEL), covering cash flow, earnings, and balance sheets.
AVITA Medical, Inc. (RCEL) Income Statement & Financial Overview
Analyze AVITA Medical, Inc.’s RCEL earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $18.51M | $18.41M | $19.55M | $15.20M |
| Cost of Revenue | $2.83M | $2.28M | $3.19M | $2.11M |
| Gross Profit | $15.68M | $16.13M | $16.36M | $13.08M |
| Gross Profit Ratio | $0.85 | $0.88 | $0.84 | $0.86 |
| R&D Expenses | $6.28M | $4.85M | $5.43M | $4.89M |
| SG&A Expenses | $21.22M | $21.23M | $24.73M | $23.82M |
| Operating Expenses | $27.51M | $26.08M | $30.16M | $28.71M |
| Total Costs & Expenses | $30.34M | $28.36M | $33.35M | $30.82M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.23M | $1.30M | $1.36M | $1.35M |
| Depreciation & Amortization | $521000.00 | $409000.00 | $310000.00 | $204000.00 |
| EBITDA | -$12.10M | -$9.86M | -$14.56M | -$13.81M |
| EBITDA Ratio | -$0.65 | -$0.54 | -$0.75 | -$0.91 |
| Operating Income | -$11.83M | -$9.96M | -$13.81M | -$15.62M |
| Operating Income Ratio | -$0.64 | -$0.54 | -$0.71 | -$1.03 |
| Other Income/Expenses (Net) | -$2.02M | -$1.61M | -$2.43M | $264000.00 |
| Income Before Tax | -$13.85M | -$11.57M | -$16.23M | -$15.36M |
| Income Before Tax Ratio | -$0.75 | -$0.63 | -$0.83 | -$1.01 |
| Income Tax Expense | $8000.00 | $19000.00 | -$28000.00 | $33000.00 |
| Net Income | -$13.86M | -$11.59M | -$16.20M | -$15.39M |
| Net Income Ratio | -$0.75 | -$0.63 | -$0.83 | -$1.01 |
| EPS | -$0.53 | -$0.44 | -$0.62 | -$0.60 |
| Diluted EPS | -$0.53 | -$0.44 | -$0.62 | -$0.60 |
| Weighted Avg Shares Outstanding | $26.25M | $26.15M | $25.98M | $25.76M |
| Weighted Avg Shares Outstanding (Diluted) | $26.25M | $26.15M | $25.98M | $25.76M |
Financial performance has remained strong, with revenue growing from $15.20M in Q2 2024 to $18.51M in Q1 2025. Gross profit continued to perform well, with margins at 85% in the latest quarter. Operating income reached -$11.83M in Q1 2025, holding a steady -64% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$12.10M. Net income dropped to -$13.86M, keeping EPS at -$0.53. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan